MARK EDWARD MCGOVERN
Medical Practice in Miami, FL
License number
Pennsylvania MD038185E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Miami, FL 33139
Pennsylvania
Pennsylvania
Personal information
See more information about MARK EDWARD MCGOVERN at radaris.comName
Address
Phone
10037 Colonnade Dr, Tampa, FL 33647
5186 NE 6Th Ave, Ft Lauderdale, FL 33334
4728 Lansing St, Philadelphia, PA 19136
3348 Nauvoo Rd, Liberty, PA 16930
521 Pasadena Ave, Jenkintown, PA 19046
Professional information
Vice President At Trans American
Position:
Vice President at Trans American
Location:
Miami/Fort Lauderdale Area
Industry:
Logistics and Supply Chain
Work:
Trans American
-
Vice President
Independent Pharmaceuticals Professional
Location:
Miami/Fort Lauderdale Area
Industry:
Pharmaceuticals
Mark Mcgovern
Location:
Miami/Fort Lauderdale Area
Industry:
Medical Practice
Pharmaceutical Compositions
US Patent:
2003012, Jul 3, 2003
Filed:
Nov 26, 2002
Appl. No.:
10/305281
Inventors:
Rene Belder - Hopewell NJ, US
Mark McGovern - Miami Beach FL, US
Mark McGovern - Miami Beach FL, US
International Classification:
A61K031/366, A61K031/225
US Classification:
514/460000, 514/548000
Abstract:
The instant invention provides methods and pharmaceutical compositions for reducing LDL cholesterol levels in mammals comprising the administration of a therapeutically effective amount of greater than 40 mg once per day of pravastatin, or a pharmaceutically acceptable salt or ester thereof, to a mammal in need of such treatment.
Pharmaceutical Compositions
US Patent:
2002018, Dec 5, 2002
Filed:
Feb 27, 2001
Appl. No.:
09/794449
Inventors:
Rene Belder - Hopewell NJ, US
Mark McGovern - Miami Beach FL, US
Mark McGovern - Miami Beach FL, US
International Classification:
A61K031/366, A61K031/22
US Classification:
514/460000, 514/548000
Abstract:
The instant invention provides methods and pharmaceutical compositions for reducing LDL cholesterol levels in mammals comprising the administration of a therapeutically effective amount of greater than 40 mg once per day of pravastatin, or a pharmaceutically acceptable salt or ester thereof, to a mammal in need of such treatment.